AstraZeneca expects US vaccine data ‘soon’ — with 50M doses ready by the end of April

AstraZeneca said it’s readying the release of data from its US-based Phase III trial, which has more than 32,000 participants, for its upcoming emergency use authorization application.

“We expect data from our US Phase III trial to be available soon, in the coming weeks, and we plan to file for emergency use authorization shortly thereafter,” a company spokesperson said via email.